GlassScriptPhysician profile
Anna Lisa Guzman
NPI 1538381512
$9,673.63
in general payments reported to CMS, 2019-2025
45 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,029 · 2022: $2,521 · 2023: $2,214 · 2024: $1,456 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032 · Education: $90.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,032.21 |
| Education | $90.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.14 | 2021-2025 | |
| Novo Nordisk INC | $867.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $769.72 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $744.20 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $439.38 | 2021-2023 | Repatha, Otezla, Prolia |
| Corcept Therapeutics | $434.07 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $422.95 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.54 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.78 | 2022-2025 | Xifaxan, Trulance |
| Insulet Corporation | $331.80 | 2021-2025 | Omnipod |
| Dexcom, INC. | $303.20 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Ironwood Pharmaceuticals, INC | $286.06 | 2021-2024 | Linzess |
| Abbott Laboratories | $272.85 | 2022-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $256.32 | 2021-2023 | Belsomra, Steglatro |
| Pfizer INC. | $246.18 | 2021-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $234.40 | 2022-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $215.33 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $202.13 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.22 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $181.11 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Daiichi Sankyo INC. | $178.21 | 2022-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $172.09 | 2021-2023 | Trintellix |
| Baxter Healthcare | $168.00 | 2022 | |
| Inspire Medical Systems, INC. | $159.22 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $136.57 | 2025 | Ams 700 |
| Glaxosmithkline, LLC. | $125.49 | 2021-2023 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $100.00 | 2021-2023 | Livalo, Seglentis |
| Genentech USA, INC. | $87.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $74.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $52.50 | 2021 | |
| Esperion Therapeutics, INC. | $52.24 | 2021-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $49.19 | 2022 | |
| Seqirus USA INC | $45.59 | 2025 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $33.03 | 2021 | |
| Phadia US INC. | $31.94 | 2021-2025 | Immunocap |
| Xeris Pharmaceuticals, INC. | $30.44 | 2021-2022 | |
| Alk-Abello, INC | $24.41 | 2025 | Odactra, Grastek, Ragwitek |
| Allergan, INC. | $22.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.33 | 2024 | Rexulti |
| Urgo Medical North America, LLC | $17.10 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Nestle Healthcare Nutrition INC. | $16.98 | 2022 | |
| Sumitomo Pharma America, INC. | $16.14 | 2024 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $14.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.91 | 2021 | |
| Phathom Pharmaceuticals, INC. | $7.58 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.